Beta Bionics, Inc.
NASDAQ Global MarketCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Sean T. Saint
- Full Time Employees
- 423
- Sector
- Healthcare
- Industry
- Medical - Equipment & Services
- Address
- 11 Hughes Irvine CA United States of America 92618
- IPO Date
- Jan 30, 2025
- CIK
- 0001674632
- Website
- betabionics.com
- Similar Companies
- Business
- Beta Bionics, Inc. (NASDAQ:BBNX) develops and commercializes automated insulin delivery systems for people with insulin-dependent diabetes. The company offers the iLet Bionic Pancreas, an FDA-cleared autonomous insulin delivery device for adults and children aged six years and older that integrates with Dexcom or FreeStyle Libre 3 Plus continuous glucose monitors to automatically compute and deliver insulin doses without requiring carb counting, correction factors, or preset basal rates; a Color iLet variant featuring a color screen and enhanced alerts; and related monthly supplies. Beta Bionics develops additional pipeline products including a tubeless Patch Pump that adheres directly to the skin, a Bihormonal iLet combining automated insulin and glucagon delivery, and an iLet configuration for insulin-dependent type 2 diabetes. Founded in 2015 and headquartered in Irvine, California, with operations in Massachusetts, the company targets people with diabetes globally, emphasizing simplified management through adaptive algorithms. Beta Bionics maintains strategic partnerships, including a collaboration and license agreement with Xeris Pharmaceuticals, Inc. for a pump-compatible glucagon formulation and a development agreement with Abbott Diabetes Care Inc. for automated insulin delivery systems. In November 2024, Beta Bionics closed a $60 million Series E funding round led by Wellington Management with participation from existing investors including Eventide Asset Management and RTW Investments to support iLet commercialization, pipeline advancement, and manufacturing expansion. The company completed its initial public offering on NASDAQ in January 2025 and reported full-year 2024 revenue of $65.1 million, reflecting 443% year-over-year growth and an install base exceeding 15,000 users. Beta Bionics continues to pursue pharmacy reimbursement for the iLet system while advancing bihormonal and patch pump initiatives.
Beta Bionics Investor Alert: Johnson Fistel Reviews Potential Claims for Shareholders
Beta Bionics to Announce Second Quarter 2026 Financial Results on July 29, 2026
Beta Bionics Investor Alert: Johnson Fistel Reviews Potential Claims for Shareholders
Beta Bionics Investor Alert: Johnson Fistel Reviews Potential Claims for Shareholders
Beta Bionics Investor Alert: Johnson Fistel Reviews Potential Claims for Shareholders
Beta Bionics Investor Alert: Johnson Fistel Reviews Potential Claims for Shareholders
Beta Bionics Investor Alert: Johnson Fistel Reviews Potential Claims for Shareholders
Johnson Fistel Continues Investigation of Beta Bionics, Inc. (BBNX)
Johnson Fistel Continues Investigation of Beta Bionics, Inc. (BBNX)
Beta Bionics (BBNX) Securities Investigation: Johnson Fistel Reviews Investor Losses Following Slower New Patient Start Growth
Beta Bionics (BBNX) Securities Investigation: Johnson Fistel Reviews Investor Losses Following Slower New Patient Start Growth
Beta Bionics (BBNX) Securities Investigation: Johnson Fistel Reviews Investor Losses Following Slower New Patient Start Growth
Beta Bionics (BBNX) Securities Investigation: Johnson Fistel Reviews Investor Losses Following Slower New Patient Start Growth
Beta Bionics (BBNX) Securities Investigation: Johnson Fistel Reviews Investor Losses Following Slower New Patient Start Growth
Robbins LLP Reminds BBNX Stockholders of its Investigation into Beta Bionics, Inc.; Contact the Firm for Information
Beta Bionics (BBNX) Securities Investigation: Johnson Fistel Reviews Investor Losses Following Slower New Patient Start Growth
Beta Bionics, Inc. (BBNX) Investigation: Johnson Fistel Investigates Investor Losses Following Slower New Patient Start Growth
Beta Bionics, Inc. Securities Fraud Investigation – Robbins LLP is Investigating Investor Losses in BBNX Due to Possible Violations of Securities Laws
Beta Bionics Investors Suffer Significant Losses After Company Reports Slower New Patient Start Growth; Contact Johnson Fistel
BBNX Shareholder Alert: Robbins LLP Reminds Beta Bionics, Inc. Stockholders that it is Investigating the Company's Officers and Directors to Determine if They Violated Securities Laws and Breached Fiduciary Duties to Shareholders